High total metabolic tumor volume on 18F-FDG-PET/CT correlates with lack of immune response in advanced melanoma patients treated with pembrolizumab.
Odrade Gondry(Onze Lieve Vrouwziekenhuis Hospital), Marleen Keyaerts(Vrije Universiteit Brussel), Emma Daeninck, Julia Katharina Schwarze(Universitair Ziekenhuis Brussel), Gil Awada(Mathys (Netherlands)), İbrahim Halil Özdemir, Teofila Seremet(University of Lausanne), Bart Neyns(Universitair Ziekenhuis Brussel), Hendrik Everaert(Universitair Ziekenhuis Brussel), Lode Goethals(Universitair Ziekenhuis Brussel), Yanina Jansen(Universitair Ziekenhuis Brussel)
Unknown
January 15, 2020
Cited by 0
Related Papers
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
|Annals of Oncology|2022|253
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
|Annals of Oncology|2020|232